Trial reportMedical science monitor : international medical journal of experimental and clinical research2013
Effect of azathioprine or mesalazine therapy on incidence of re-hospitalization in sub-occlusive ileocecal Crohn's disease patients.
Trial report in Medical science monitor : international medical journal of experimental and clinical research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Pancreatitis associated with azathioprine and 6-mercaptopurine use in Crohn's disease: a systematic review.Frontline gastroenterology · 2021Pooled it
- Systematic review: medical therapy for fibrostenosing Crohn's disease.Alimentary pharmacology & therapeutics · 2020Pooled it
- Interventions to Promote Early Discharge and Avoid Inappropriate Hospital (Re)Admission: A Systematic Review.International journal of environmental research and public health · 2019Pooled it
- Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.The Cochrane database of systematic reviews · 2015Pooled it
- Combined diosmectite and mesalazine treatment for mild-to-moderate ulcerative colitis: a randomized, placebo-controlled study.Medical science monitor : international medical journal of experimental and clinical research · 2015Trial
- Azathioprine is more effective than mesalazine at preventing recurrent bowel obstruction in patients with ileocecal Crohn's disease.Medical science monitor : international medical journal of experimental and clinical research · 2014Trial
- Vedolizumab for stricturing Crohn's disease of the terminal ileum - an international multicenter cohort study.BMC gastroenterology · 2026Observational
- Phytochemical Compounds as Promising Therapeutics for Intestinal Fibrosis in Inflammatory Bowel Disease: A Critical Review.Nutrients · 2024Review
- Medical, Endoscopic and Surgical Management of Stricturing Crohn's Disease: Current Clinical Practice.Journal of clinical medicine · 2022Review
- Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy.Frontiers in immunology · 2022Review
- Prevention and Treatment of Stricturing Crohn's Disease - Perspectives and Challenges.Expert review of gastroenterology & hepatology · 2021Review
- Management of Inflammatory Bowel Disease Patients With Clinical Care Pathways Reduces Emergency Department Utilization.Crohn's & colitis 360 · 2020Article
- Fibrostenotic strictures in Crohn's disease.Intestinal research · 2020Review
- Natural history, diagnosis and treatment approach to fibrostenosing Crohn's disease.United European gastroenterology journal · 2020Review
- Anemia in inflammatory bowel disease outpatients: prevalence, risk factors, and etiology.BioMed research international · 2015Article
- A guide to prepare patients with inflammatory bowel diseases for anti-TNF-α therapy.Medical science monitor : international medical journal of experimental and clinical research · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough the cost of Crohn's disease (CD) treatment differs considerably, hospitalization and surgery costs account for most of the total treatment cost. Decreasing hospitalization and surgery rates are pivotal issues in reducing health-care costs. MATERIAL/METHODS We evaluated the effect of azathioprine (AZA) compared with mesalazine on incidence of re-hospitalizations due to all causes and for CD-related surgeries. In this controlled, randomized study, 72 subjects with sub-occlusive ileocecal CD were randomized for AZA (2-3 mg/kg per day) or mesalazine (3.2 g per day) therapy during a 3-year period. The primary end point was the re-hospitalization proportion due to all causes, as well as for surgical procedures during this period evaluated between the groups.
resultsOn an intention-to-treat basis, the proportion of patients re-hospitalized within 36 months due to all causes was lower in patients treated with AZA compared to those on mesalazine (0.39 vs. 0.83, respectively; p=0.035). The AZA group had also significantly lower proportions of re-hospitalization for surgical intervention (0.25 vs. 0.56, respectively; p=0.011). The number of admissions (0.70 vs. 1.41, p=0.001) and the length of re-hospitalization (3.8 vs. 7.7 days; p=0.002) were both lower in AZA patients.
conclusionsPatients with sub-occlusive ileocecal CD treated with AZA had lower re-hospitalization rates due to all causes and for surgical management of CD compared to those treated with mesalazine during a 3-year period. The long-term use of AZA in ileocecal CD patients recovering from a sub-occlusion episode can save healthcare costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.